ArticleExperimental & molecular medicine2026
Non-reproductive tumor progression impairs ovarian function through CXCL10-IL18R1 axis.
Article in Experimental & molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ovary is susceptible to harmful environmental factors. Tumor progression (TP) is an intracorporal harmful environmental factor. It is known that TP could impair adjacent tissues through pro-inflammatory cytokines. However, it is unclear whether and how non-reproductive tumor progression (NRTP) impairs ovarian function. In this study, we used MCA205 (mouse fibrosarcoma) cell-allotransplanted B6 mice as a basic model (M group); meanwhile, we established two popular therapeutic models - PD-1 monoclonal antibody injection in allotransplanted mice (PD-1 group) and whole cancer cell vaccine (WCV) injection in allotransplanted mice (WCV group) - to facilitate the discovery process. As expected, TP in M group decreased ovarian function multifacetedly. Interestingly, WCV injection significantly reversed these abnormalities, whereas PD-1 did not. Next, plasma cytokine microarray characterized CXCL10 with both the biggest increment in M group and best rescue in WCV group. Next, we baited the only CXCL10 receptor, IL18R1, within ovaries. Next, we found that CXCL10 directly bound to IL18R1 to impair ovarian function through three pathways: inducing ovarian fibrosis through p-JNK→p-JUN → COL1A1, promoting primordial follicle overactivation through p-AKT→p-FOXO3A, and increasing ovarian inflammation through p-P65 → IFNγ. We have also preliminarily verified the CXCL10-IL18R1 axis and the upper three downstream pathways in MC38 (mouse colon cancer cells)-allotransplanted and B16F10 (mouse melanoma cells)-allotransplanted B6 mice. Finally, we rescued the decreased ovarian function in the M group by blocking the CXCL10 → IL18R1 pathway with CXCL10 antibody or a CXCL10-IL18R1 interface peptide, CIBB. This study provides mechanical evidence and translational strategies of how NRTP impairs ovarian functions and how to target-protect ovaries under NRTP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.